RxDoctor Payments Data

Umangi Patel, MD

Gastroenterology · Dallas, TXNPI 1649415951

Payments from drug & device makers

$1,352in general payments, 2019–2025

Across 45 payments — averaging $30.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$508
  • Madrigal Pharmaceuticals$154
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • Phathom Pharmaceuticals, Inc.$101
  • Medtronic$95
  • Johnson & Johnson$65
  • plus $318 from 7 others

What the payments were for

  • Food & beverage$1,33999%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 25th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$45,717
Medicare patients
199
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$22,042
Mesalamine11$9,729
Budesonide DrBudesonide30$4,695
Pantoprazole Sodium98$1,045
Colestipol Hcl11$997
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg35$809
CholestyramineCholestyramine (With Sugar)11$789
Bethanechol Chloride11$576
Dicyclomine Hcl36$403
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$383
Omeprazole27$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$508$22,04226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →